$15,000 of AXOGEN INC. lobbying was just disclosed, from Q2 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues relating to sensation loss after mastectomy."
You can find more data on corporate lobbying on Quiver Quantitative.
AXGN Insider Trading Activity
AXGN insiders have traded $AXGN stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $AXGN stock by insiders over the last 6 months:
- JOSEPH A. TYNDALL has made 0 purchases and 4 sales selling 49,518 shares for an estimated $542,760.
- ERICK WAYNE DEVINNEY (Chief Innovation Officer) sold 15,111 shares for an estimated $264,442
- AMY MCBRIDE WENDELL has made 0 purchases and 2 sales selling 9,073 shares for an estimated $143,314.
- GUIDO J NEELS sold 4,073 shares for an estimated $43,214
- JOHN JOHNSON sold 4,073 shares for an estimated $43,214
- WILLIAM P. MR. BURKE sold 4,073 shares for an estimated $43,214
- ALAN M LEVINE sold 4,073 shares for an estimated $43,214
- KATHY JOHNSON WEILER sold 4,073 shares for an estimated $43,214
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
AXGN Hedge Fund Activity
We have seen 96 institutional investors add shares of AXGN stock to their portfolio, and 72 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 1,509,826 shares (-51.1%) from their portfolio in Q1 2025, for an estimated $27,931,781
- WASATCH ADVISORS LP added 774,633 shares (+inf%) to their portfolio in Q1 2025, for an estimated $14,330,710
- ARROWMARK COLORADO HOLDINGS LLC removed 657,689 shares (-29.2%) from their portfolio in Q1 2025, for an estimated $12,167,246
- MARSHALL WACE, LLP added 576,664 shares (+629.6%) to their portfolio in Q1 2025, for an estimated $10,668,284
- BALYASNY ASSET MANAGEMENT L.P. added 380,248 shares (+126.8%) to their portfolio in Q1 2025, for an estimated $7,034,588
- INVESCO LTD. added 365,237 shares (+2124.5%) to their portfolio in Q1 2025, for an estimated $6,756,884
- QUBE RESEARCH & TECHNOLOGIES LTD added 282,700 shares (+191.5%) to their portfolio in Q1 2025, for an estimated $5,229,950
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AXGN Analyst Ratings
Wall Street analysts have issued reports on $AXGN in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 05/13/2025
- Lake Street issued a "Buy" rating on 03/17/2025
- Cantor Fitzgerald issued a "Overweight" rating on 03/05/2025
- Citizens Capital Markets issued a "Market Outperform" rating on 03/05/2025
To track analyst ratings and price targets for AXGN, check out Quiver Quantitative's $AXGN forecast page.
AXGN Price Targets
Multiple analysts have issued price targets for $AXGN recently. We have seen 5 analysts offer price targets for $AXGN in the last 6 months, with a median target of $26.0.
Here are some recent targets:
- Caitlin Cronin from Canaccord Genuity set a target price of $24.0 on 05/13/2025
- Frank Takkinen from Lake Street set a target price of $30.0 on 03/17/2025
- Ross Osborn from Cantor Fitzgerald set a target price of $24.0 on 03/05/2025
- David Turkaly from Citizens Capital Markets set a target price of $26.0 on 03/05/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
